BioPharmSignal logoBioPharmSignal

Biotech News

MannKind to Present at Jefferies Global Healthcare Conference

MannKind (MNKD)MannKindConference / presentation

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.

Related news

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

VANIVivani Medical2026-05-28 12:30 EST

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-05-27 12:00 EST

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

ALTAltimmune2026-09-03 12:00 EST

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

MLYSMineralys Therapeutics2026-08-26 12:00 EST

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States